Contact Information

The Genzyme Renal Innovations Grant Program (GRIP) distributes individual grants to researchers, clinicians and fellows in the field of Nephrology. GRIP was established to support the advancement of medical knowledge and practice in kidney diseases through innovative research projects in Nephrology. It represents the commitment Genzyme has made to enhance the care of patients with kidney disease. As we pursue new knowledge and understanding together, our hope is to sustain an enduring partnership with the worldwide Nephrology community.

Grant topics for 2009 will be announced at the American Society of Nephrology (ASN) annual meeting in November 2008. All applicants must submit a Letter of Intent which is due in January 2009. If the proposed research is selected, the applicant will be notified via email and asked to submit a full research proposal. Full research proposals are due before March 31, 2009 and winners will be announced at the annual European Dialysis and Transplant Association (EDTA) meeting held in mid 2009. An independent medical review board composed of worldwide thought leaders in the Nephrology community will review and evaluate all Letters of Intent and proposals.

For questions regarding the GRIP program or grant application process, please email grip@genzyme.com. You may also call within the US 1-800-326-7002, x16658, or +1-617-768-6658 outside the US, and speak with Susan Kapurch, Grant Program Administrator.

Hectorol is indicated for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease (capsules) and in patients with chronic kidney disease on dialysis (capsules and injection)∙ Hectorol is contraindicated in patients with a tendency towards hypercalcemia or evidence of vitamin D toxicity ∙ Overdosage of any form of vitamin D is dangerous∙ Acute hypercalcemia may exacerbate tendencies for cardiac arrhythmias and seizures and may potentiate the action of digitalis drugs∙ Chronic hypercalcemia can lead to generalized vascular and soft tissue calcification∙ Pharmacologic doses of vitamin D and its derivatives should be withheld during Hectorol treatment to avoid possible additive effects and hypercalcemia∙ Magnesium-containing antacids and Hectorol should not be administered concomitantly∙ Adverse effects of Hectorol treatment are: hypercalcemia, hyperphosphatemia, hypercalciuria, and oversuppression of iPTH∙ Adverse events reported by ³ 5% of the Hectorol-treated predialysis patients included: infection, chest pain, constipation, dyspepsia, anemia, dehydration, depression, hypertonia, insomnia, paresthesia, increased cough, dyspnea and rhinitis ∙ Adverse events reported by ³ 5% of the Hectorol-treated dialysis patients included: headache, malaise, bradycardia, nausea/vomiting, edema, dizziness, dyspnea, and pruritus. See Hectorol Capsules Full Prescribing Information or Hectorol Injection Full Prescribing Information.


	Terms and Conditions of Use \| Privacy Policy \| ©	2008 Genzyme Corporation. All rights reserved.